Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Xgeva Rejection Shows What’s Needed For Non-Metastatic CRPC Approvals

Related Content

Amgen Needs To Show <em>Xgeva</em> Does More Than Delay Bone Metastases, ODAC Says

Feb 13 2012

Zytiga Study Supports Expansion To Early Patient Population

Mar 08 2012

Medivation Aims To Capture Prostate Cancer Market, One Trial At A Time

Nov 14 2011

Amgen's Bone Drug Xgeva Delays Pain From Prostate Cancer Metastases

May 17 2011

Prostate Cancer Market Snapshot: More Than Provenge

Nov 22 2010

Related Companies

Amgen, Inc.

Dendreon Corporation

Johnson & Johnson

Medivation, Inc.

Astellas Pharma, Inc.

Additional Topics

Regulation Clinical Trials

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window